Farther Finance Advisors LLC Increases Position in Hims & Hers Health, Inc. $HIMS

Farther Finance Advisors LLC grew its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 5.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,584 shares of the company’s stock after acquiring an additional 462 shares during the period. Farther Finance Advisors LLC’s holdings in Hims & Hers Health were worth $428,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health in the first quarter worth about $30,000. UMB Bank n.a. grew its holdings in shares of Hims & Hers Health by 247.5% during the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock valued at $39,000 after buying an additional 933 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Hims & Hers Health during the first quarter valued at approximately $41,000. Larson Financial Group LLC lifted its position in Hims & Hers Health by 47.7% during the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock valued at $42,000 after purchasing an additional 458 shares during the period. Finally, Webster Bank N. A. lifted its position in Hims & Hers Health by 229.1% during the second quarter. Webster Bank N. A. now owns 905 shares of the company’s stock valued at $45,000 after purchasing an additional 630 shares during the period. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 145,000 shares of the business’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the transaction, the chief financial officer directly owned 128,984 shares of the company’s stock, valued at approximately $7,139,264.40. The trade was a 52.92% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Patrick Harrison Carroll sold 60,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the sale, the insider owned 169,940 shares in the company, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,535,090 shares of company stock valued at $78,294,662. 17.71% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HIMS. Zacks Research downgraded shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 19th. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Citigroup reaffirmed a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Wall Street Zen cut shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Two investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $58.35 on Monday. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. The company has a market capitalization of $13.19 billion, a PE ratio of 72.93, a price-to-earnings-growth ratio of 3.94 and a beta of 2.14. Hims & Hers Health, Inc. has a 1 year low of $16.05 and a 1 year high of $72.98. The company’s fifty day moving average price is $51.22 and its 200 day moving average price is $46.54.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. During the same quarter in the previous year, the business posted $0.06 earnings per share. Hims & Hers Health’s revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.